Firefly Bio

Company Deals Drug

J&J to Acquire Firefly Bio for $1 Billion, Adding Proprietary DAC Platform Targeting KRAS-Driven Tumors

Fineline Cube Jun 9, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced today a definitive agreement to acquire Firefly Bio,...

Company Drug

Jikeshu (Sebaloxavir Marboxil) Receives NMPA Approval for Adolescent Influenza Treatment, Expanding Single-Dose Category 1 Antiviral Franchise

Company Drug

CSPC Pharmaceutical Receives FDA Clearance for Once-Monthly Semaglutide SYH9017 in Weight Management, Challenging Weekly GLP-1 Standard

Company Drug

Lepu Medical Receives TGA Approval for Phase I Trial of Dual-Targeting siRNA MWX205 Against PCSK9 and ANGPTL3 in Australia

Company Deals

Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma’s Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal